Drug
hzVSF-v13
hzVSF-v13 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
NCT04679350
completedphase_2
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
NCT04679415
completedphase_2
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
NCT04676971
completedphase_1
Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
NCT03653208
Clinical Trials (4)
Showing 4 of 4 trials
NCT04679350Phase 2
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
NCT04679415Phase 2
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
NCT04676971Phase 2
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
NCT03653208Phase 1
Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4